Member Info for inanaco

Thing is the cancers have not returned for many patients on the trial as per the swimmer chart, so its self explanatory but your right to draw this to the markets attention. Great post yesterday .. i rarely REC posts, so that is one of the Good ones worthy of a reprint.

SCIB1 ....Fantastic phase 1/2 plus double dose at 8mg trials run in adjuvant Melanoma 5 year proof of cancer patient survival no toxicity SCIB1 combo about to start all the evidence from other combo trials points to successful synergy with keytruda, and Scancells own data in mice is a significant increase in efficacy of both products compared to using as a mono therapy and of course no added toxicity SCIB2 taken up by CRUK with the potential to increase to 4 targets at minimal cost to Scancell Modi1 in manufacture 4 targets 100% success in mice, and Memory response to re-challenge Modi2 defined 4 targets Modi3 could be completely supported by the Grand Challenge with a 20m grant going after the hardest to treat cancers Moditope TCR collaboration with BioNtech with a commercial outcome at the end or sooner. other immunobodies in development Glycan Platform now added to the IP could be used to boost inflammation on cold cancers .. and run complimentary to immunobody and moditope, again potentially increasing efficacy (making it difficult for other products to prove against scancell superiority) Other "stress induced" PTM has been identified, as yet full details unknown. (moditope is a PTM) �11m in the bank sufficient to complete SCIB1 trials and initiate Modi1 trials. Moditope 37 epitopes discovered to induce an immune response (modi1 uses 3) Potential to treat every cancer (not sure on blood cancers) This reads like the oncology pipeline of a Major Pharma MCAP 45m

lets see how it all plays out ... as long as we have a basic understanding its sufficient

its a platform that can support any vaccine or checkpoint inhibitor or all three ... Grand Challenge .....

Both mAbs showed strong tumor reactivity, binding to 71% (147/208) of colorectal, 81% (155/192) of pancreatic, 54% (52/96) of gastric, 23% (62/274) of non-small cell lung and 31% (66/217) of ovarian tumor tissue in combination with a restricted normal tissue distribution. In colorectal cancer, possible inclusion in Grand Challenge ? look at that 54% binding on pancreatic

I had read about these technology a few years ago, indeed had discussion with Lindy on it . at the time, Boom will remember as we even discussed investment if it was spin off .. Sent: 17 March 2015 16:42 To: Lindy Durrant Subject: Re: Hi Lindy Hi lindy hope all is well Is this Scancell or The University ? or both ... another joint program http://clincancerres.aacrjournals.org/content/early/2015/03/13/1078-0432.CCR-14-3030.abstract Kind regards

really just research antibodies ... Immunobody is a antibody however a pretty advanced one ... it locks onto the dendritic system to prime t cells with its payload ... However, anti-idiotypic antibodies mimicking antigens have been shown to stimulate both antibody and T cell responses. The latter are due to T cell mimotopes expressed within the complementarity-determining regions (CDRs) of antibodies that are efficiently presented to dendritic cells in vivo. Based on this observation we have designed a DNA vaccine platform called ImmunoBody�, where cytotoxic T lymphocyte (CTL) and helper T cell epitopes replace CDR regions within the framework of a human IgG1 antibody.

Mab that can search out specific sugars ..... Mab that can kill cells ... Put them together .... a sugar searching killing machine ....

book build ......... by panmure = �7m

so IMHO first part is Mabs that can find the sugar second part they are then be inserted into a modified antibody that can directly kill .......... """Together these offer a complementary platform"""

yes ... Ray ... But this has two parts ... and this bit is .... interesting Alongside this, Scancell has also acquired a proprietary technology to enable the modification of the constant region (FC) of a human antibody to allow direct tumour killing.

ET stands for �positron emission tomography�. It is a nuclear medicine imaging test in which a small amount of liquid radioactive material is injected into the body and is used to diagnose a variety of diseases, including many types of cancers, and brain and heart disease. The radioactive substance most commonly used in PET scanning is a simple sugar (like glucose) called FDG, which stands for �fluorodeoxyglucose�. It is injected into the bloodstream and accumulates in the body where it gives off energy in the form of gamma rays. These are detected by the PET scanner and a computer converts the signals into detailed pictures or images showing how tissue and organs are working. If you are having an FDG-PET, your sugar metabolism (how sugar is used by your body) is imaged. This is commonly used for cancer imaging, as the cancer cells need sugar to grow. FDG is also useful for imaging inflammatory or infective processes, and for imaging brain metabolism. what scancell is doing after the sugar displayed by the cell .... Glycans which are saccharides

I agree wild ... to many are not focusing on what is important, and indeed why would you sell at 12.1 when a buy order of �7m came in at 12p .... the market has way to many numpties ...

what is the relationship between the scan and the MAB ?

C7 ... I dont have a clue what your on about

if you mean injecting sugars to track .. sugar is a pretty broad description .........

if the cell is dead you will not see it ...... simple the cancer will shrink

toshwings .. appraisal of the latest RNS on the science ..........

Advances in understanding the pattern of sugars (glycans) that adorn cells have highlighted important differences between those on tumour cells versus their normal counterparts. This altered sugar signature of tumour cells is intricately linked to the majority of cancer cell biology hallmarks. Antibodies that target such tumour glycan signatures, when coupled to a novel approach to invoke an immune response on binding, provide an attractive strategy for immunotherapy and forms the basis of the platform technology developed by Prof. Lindy Durrant and her team at the Nottingham University Therapeutic Antibody Centre (NUTAC).1 ........ understand the science and the investment is easy ...

The key to kill cancer Now this new platform ...... could induce inflammation and as i see it, completely bypass all the cancers ability to cloak itself to the immune system ... because these MAB's dont get turned off like T cells ... So Immunobody can activate an adaptive response but struggles against big tumours because of the cloaking device so needs PD1 to unlock that ... PD1-li goes active on inflammation of the adaptive response but is squashed by the PD1 .. and the reason why PD1 on its own fails is because no Innate system activates the immune system Modiotope is similar No expression of the epitope without inflammation ... so if you can induce cell death by chemo ... PD1 can work better as seen in trials, why because cell death promotes inflammation ......... inducing an innate response which turns adaptive making the PD1 effective so our new platform does this ......... my guess toxic free, because its target is sugars only found on cancer https://www.ncbi.nlm.nih.gov/pubmed/18039143 When cells die in vivo, they trigger an inflammatory response. The ensuing hyperemia, leak of plasma proteins, and recruitment of leukocytes serve a number of useful functions in host defense and tissue repair. However, this response can also cause tissue damage and contribute to the pathogenesis of a number of diseases. Given the key role of inflammation in these processes, it is important to understand the underlying mechanisms that drive this response. Injured cells release danger signals that alert the host to cell death. Some of these molecules are recognized by cellular receptors that stimulate the generation of proinflammatory mediators. Other molecules released by dead cells stimulate the generation of mediators from extracellular sources. The resulting mediators then orchestrate the inflammatory response, eliciting its various vascular and cellular components. Dead cells also release danger signals that activate dendritic cells and promote the generation of immune responses to antigens. Here we review what is presently known about the sterile inflammatory response and its underlying mechanisms. So when you only look at the Head line news 12p .... just remember the other news not yet priced in ... Scancell Holdings plc, ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatment of cancer, announces that it has entered into an agreement with the University of Nottingham to acquire a number of novel monoclonal antibodies to tumour-associated glycans ("Assigned Antibodies"). Alongside this, Scancell has also acquired a proprietary technology to enable the modification of the constant region (FC) of a human antibody to allow direct tumour killing. Together these offer a complementary platform to Scancell's existing cancer immunotherapy platforms, ImmunoBody� and Moditope�. Advances in understanding the pattern of sugars (glycans) that adorn cells ha